Anne-Sophie Pailhes-Jimenez

Anne-Sophie Pailhes-Jimenez

Auto-generated profile, based on publicly available information

Anne-Sophie Pailhes-Jimenez

ANGLE Europe Limited, Guildford - UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Journal of Circulating Biomarkers
Verified
Journal Article
Open access
PDF file
ATAmy Templeman
Amy Templeman
MMMichael Craig Miller
Michael Craig Miller
MCMartin J. Cooke
Martin J. Cooke
DODaniel J. O'SHannessy
Daniel J. O'SHannessy
YGYuwaraj Gurung
Yuwaraj Gurung
APAnne-Sophie Pailhes-Jimenez
Anne-Sophie Pailhes-Jimenez
Introduction: The Parsortix® PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device for the capture and harvest of circulating tumor cells from whole blood based on cell size and deformability. This report details the analytical characterization of linearity, detection limit, precision, and reproducibility for this device. Methods: System performance was determined using K2-EDTA blood samples collected from self-declared healthy female volunteers (HVs) and MBC patients spiked with prelabeled cultured breast cancer cell lines (SKBR3, MCF7, or Hs578T). Samples were processed on Parsortix® PC1 systems and captured cells were harvested and enumerated. Results: The system captured and harvested live SKBR3, MCF7, and Hs578T cells and fixed SKBR3 cells linearly between 2 and ~100 cells, with average harvest rates of 69%, 73%, 79%, and 90%, respectively. To harvest ≥1 cell ≥95% of the time, the system required 3, 5 or 4 live SKBR3, MCF7 or Hs578T cells, respectively. Average harvest rates from precision studies using 5, 10, and ~50 live cells spiked into blood for each cell line ranged from 63.5% to 76.2%, with repeatability and reproducibility percent coefficient of variation (%CV) estimates ranging from 12.3% to 32.4% and 13.3% to 34.1%, respectively. Average harvest rates using ~20 fixed SKBR3 cells spiked into HV and MBC patient blood samples were 75.0% ± 16.1% (%CV = 22.3%) and 68.4% ± 14.3% (%CV = 21.1%), respectively. Conclusions: These evaluations demonstrate the Parsortix® PC1 system linearly and reproducibly harvests tumor cells from blood over a range of 1 to ~100 cells.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
AMAmina Mezni
Amina Mezni
MHMatthew Hardy
Matthew Hardy
MCMariacristina Ciccioli
Mariacristina Ciccioli
APAnne-Sophie Pailhes-Jimenez
Anne-Sophie Pailhes-Jimenez
Introduction: Isolation of circulating tumor cells (CTCs) is widely recognised as a prognostic biomarker in metastatic breast cancer. Recently, it was shown that CTC clearance following specific therapies may predict chemosensitivity in triple negative breast cancer (TNBC) patients. However, a limited amount of CTC research is available in TNBC due to the inability of epitope-dependent CTC platforms to capture CTCs in a sufficient proportion of patients, especially when evaluating non-metastatic patients (Stage I-III). ANGLE has developed a Research Use Only (RUO) workflow including the Parsortix® system, an epitope-independent microfluidic device that isolates and harvests rare cells from blood based on their size and deformability, followed by an immunofluorescent (IF) assay for the identification and characterization of CTCs. This five-color multiplex IF assay enables the identification of both epithelial and mesenchymal CTCs as well as the investigation of other targets of interest on the CTCs. Methods: 7.5mL of peripheral blood drawn into a Streck CellFree DNA Blood Collection Tube from 11 TNBC patients (four Stage IV and seven Stage IIIa) was processed on Parsortix® system between 96 and 144 hours post collection. Harvested CTCs were cytospun onto a charged slide and immunofluorescently stained using an optimised antibody panel allowing for detection of epithelial and mesenchymal CTCs. Stained slides were imaged using a BioView Allegro Plus automated imaging system. Results: CTCs were identified in 9 (82%) of the 11 TNBC patients, with a median of 6 and mean of 30 CTCs identified per patient. CTC clusters were harvested by the Parsortix® system and were observed in the majority (8/9) of the CTC-positive patients. Cluster size ranged from 2-68 CTCs per cluster, and the number of clusters per patient ranged from 1-50. Phenotypically, a large proportion of the CTCs identified expressed only mesenchymal markers (80%), with the remainder expressing both epithelial and mesenchymal markers (20%). In 6 of the 7 non-metastatic (Stage IIIa) patients, high numbers of CTC clusters were detected. Lower numbers of CTC clusters were detected in 3 (75%) of the 4 metastatic (Stage IV) patients. Conclusions: This study demonstrated the ability of ANGLE’s multiplex IF assay to detect and phenotype CTCs. The proportion of non-metastatic TNBC patients found to have CTCs was much higher compared to previous reports using epitope-dependent systems (82% vs 25%). This highlights the advantages of epitope-independent CTC capture in TNBC. ANGLE’s RUO Parsortix® system and multiplex IF assay provide an efficient solution for the harvesting and characterization of multiple CTC phenotypes, with the added advantage of being able to process the blood between 96 and 144 hours post collection, allowing for the shipment of samples at room temperature for centralised analysis in support of global clinical trials. Citation Format: Amina Mezni, Matthew Hardy, Mariacristina Ciccioli, Anne-Sophie Pailhes-Jimenez. Epithelial and mesenchymal CTC detection in triple negative breast cancer patients using ANGLE’s Parsortix®system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 969.